Array BioPharma
Data Breaches, Cyber Attacks and Security Report  ᛫ 
Last updated September 21, 2019

About Array BioPharma

Company Overview

Array BioPharma is a U.S.-based, clinical stage, publicly traded pharmaceutical company founded in Boulder, Colorado (NASDAQ:ARRY) that is included in the NASDAQ Biotechnology Index.The company has engaged in collaborations with Pfizer and Merck to study several cancer targeting drug combinations. In July 2013 the company partnered with Loxo Oncology to develop cancer drugs, in November 2015 the company partnered with Pierre Fabre and the company also partnered with Ono Pharmaceutical in March 2016 to test the combination of binimetinib and encorafenib while retaining commercialization rights in the U.S. and other markets.In 2017 it spun out one of its programs into a subsidiary called Yarra; the asset was a molecule called ARRY-797 that was in a Phase II trial for cardiomyopathy.In March 2018 Array sued AstraZeneca for breach of contract, saying that AZ owed it a 12% royalty on a portion of the $1.6 billion upfront payment that Merck had paid to AZ in a deal for selumetinib, which Array said it had licensed to AZ in 2003.In June 2018, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) were approved by the FDA for the treatment of people with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma.





Data Breaches and Security News

Array BioPharma Security Rating

Sorry, this security report couldn't be loaded at this time. Please try again later.

UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Array BioPharma is implementing good security practices.

Passed Checks

Passed{{ passedCheck.passTitle }}

Failed Checks

Warning{{ failedCheck.failTitle }}

View a free security report for Array BioPharma

Get full security report ›

Related posts

Read more about the latest issues in cybersecurity

More security reports

Compare Array BioPharma's security performance with other companies